Technical Analysis for BDSI - BioDelivery Sciences International, Inc.

Grade Last Price % Change Price Change
grade B 4.91 -1.41% -0.07
BDSI closed down 1.41 percent on Monday, March 18, 2019, on 1.15 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical BDSI trend table...

Date Alert Name Type % Chg
Mar 18 Narrow Range Bar Range Contraction 0.00%
Mar 15 Crossed Above 20 DMA Bullish -1.41%
Mar 15 Calm After Storm Range Contraction -1.41%
Mar 15 Doji - Bearish? Reversal -1.41%
Mar 15 Earnings Movers Other -1.41%
Mar 15 Gapped Up Strength -1.41%
Mar 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 6.28%
Mar 14 Calm After Storm Range Contraction 6.28%
Mar 14 Narrow Range Bar Range Contraction 6.28%
Mar 14 NR7 Range Contraction 6.28%

Older signals for BDSI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapeutics in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) drug delivery technology that consists of a small, bi-layered erodible polymer film for application to the buccal mucosa in the development of its products. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer; BEMA Buprenorphine that is in Phase III trial for the treatment of moderate to severe chronic pain in a mixed opioid naïve and opioid experienced population; BEMA Buprenorphine/Naloxone, which is in development stage for the treatment of opioid dependence; and BEMA Granisetron for the prevention of nausea and vomiting associated with cancer therapies. The company has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Cancer Pharmaceutical Pain Drugs Pain Management Euphoriants Morphinans Opioids Nausea Cancer Therapies Vomiting Fentanyl Opioid Severe Chronic Pain Buprenorphine Drug Delivery Technology Drug Rehabilitation Opioid Antagonists Breakthrough Pain Naloxone
Is BDSI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.21
52 Week Low 1.7
Average Volume 850,179
200-Day Moving Average 3.4663
50-Day Moving Average 4.4966
20-Day Moving Average 4.8195
10-Day Moving Average 4.757
Average True Range 0.2611
ADX 20.31
+DI 22.1386
-DI 18.4748
Chandelier Exit (Long, 3 ATRs ) 4.4267
Chandelier Exit (Short, 3 ATRs ) 5.0933
Upper Bollinger Band 5.1063
Lower Bollinger Band 4.5327
Percent B (%b) 0.66
BandWidth 11.90165
MACD Line 0.0864
MACD Signal Line 0.1079
MACD Histogram -0.0215
Fundamentals Value
Market Cap 272.38 Million
Num Shares 55.5 Million
EPS 0.03
Price-to-Earnings (P/E) Ratio 163.67
Price-to-Sales 3.69
Price-to-Book 6.22
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.11
Resistance 3 (R3) 5.11 5.06 5.07
Resistance 2 (R2) 5.06 5.01 5.05 5.06
Resistance 1 (R1) 4.98 4.98 4.96 4.98 5.05
Pivot Point 4.93 4.93 4.91 4.92 4.93
Support 1 (S1) 4.85 4.88 4.83 4.85 4.77
Support 2 (S2) 4.80 4.85 4.79 4.76
Support 3 (S3) 4.72 4.80 4.75
Support 4 (S4) 4.72